Standardized MR Perfusion Scoring System for Evaluation of Sequential Perfusion Changes and Surgical Outcome of Moyamoya Disease

References

1. 1.↵
   2. Chen PC,
   3. Yang SH,
   4. Chien KL, et al

   . Epidemiology of moyamoya disease in Taiwan: a nationwide population-based study. Stroke 2014;45:1258–63 doi:10.1161/STROKEAHA.113.004160 pmid:24676775

   Abstract/FREE Full Text
2. 2.↵
   2. Teo MK,
   3. Madhugiri VS,
   4. Steinberg GK

   . Editorial: direct versus indirect bypass for moyamoya disease—ongoing controversy. J Neurosurg 2017;126:1520–22 doi:10.3171/2015.10.JNS152025 pmid:27471893

   CrossRefPubMed
3. 3.↵
   2. Macyszyn L,
   3. Attiah M,
   4. Ma TS, et al

   . Direct versus indirect revascularization procedures for moyamoya disease: a comparative effectiveness study. J Neurosurg 2017;126:1523–29 doi:10.3171/2015.8.JNS15504 pmid:27471892

   CrossRefPubMed
4. 4.↵
   2. Uchino H,
   3. Kim JH,
   4. Fujima N, et al

   . Synergistic interactions between direct and indirect bypasses in combined procedures: the significance of indirect bypasses in moyamoya disease. Neurosurgery 2017;80:201–09 doi:10.1227/NEU.0000000000001201 pmid:28175916

   CrossRefPubMed
5. 5.↵
   2. Dusick JR,
   3. Gonzalez NR,
   4. Martin NA

   . Clinical and angiographic outcomes from indirect revascularization surgery for moyamoya disease in adults and children: a review of 63 procedures. Neurosurgery 2011;68:34–43; discussion 43 doi:10.1227/NEU.0b013e3181fc5ec2 pmid:21150753

   CrossRefPubMed
6. 6.↵
   2. Park SE,
   3. Kim JS,
   4. Park EK, et al

   . Direct versus indirect revascularization in the treatment of moyamoya disease. J Neurosurg 2018;129:480–89 doi:10.3171/2017.5.JNS17353 pmid:29076784

   CrossRefPubMed
7. 7.↵
   2. Lin N,
   3. Aronson JP,
   4. Manjila S, et al

   . Treatment of moyamoya disease in the adult population with pial synangiosis. J Neurosurg 2014;120:612–17 doi:10.3171/2013.11.JNS131027 pmid:24405066

   CrossRefPubMed
8. 8.↵
   2. Suzuki J,
   3. Takaku A

   . Cerebrovascular “moyamoya” disease: disease showing abnormal net-like vessels in base of brain. Arch Neurol 1969;20:288–99 doi:10.1001/archneur.1969.00480090076012 pmid:5775283

   CrossRefPubMedWeb of Science
9. 9.↵
   2. Matsushima Y,
   3. Inaba Y

   . Moyamoya disease in children and its surgical treatment: introduction of a new surgical procedure and its follow-up angiograms. Childs Brain 1984;11:155–70 pmid:6723433

   PubMedWeb of Science
10. 10.↵
    2. Miller JH,
    3. Khonsary A,
    4. Raffel C

    . The scintigraphic appearance of childhood moyamoya disease on cerebral perfusion imaging. Pediatr Radiol 1996;26:833–38 doi:10.1007/BF03178033 pmid:8929293

    CrossRefPubMed
11. 11.↵
    2. Lee SK,
    3. Kim DI,
    4. Jeong EK, et al

    . Postoperative evaluation of moyamoya disease with perfusion-weighted MR imaging: initial experience. AJNR Am J Neuroradiol 2003;24:741–47 pmid:12695215

    Abstract/FREE Full Text
12. 12.↵
    2. Kang KH,
    3. Kim HS,
    4. Kim SY

    . Quantitative cerebrovascular reserve measured by acetazolamide-challenged dynamic CT perfusion in ischemic adult moyamoya disease: initial experience with angiographic correlation. AJNR Am J Neuroradiol 2008;29:1487–93 doi:10.3174/ajnr.A1129 pmid:18499785

    Abstract/FREE Full Text
13. 13.↵
    2. Touho H,
    3. Karasawa J,
    4. Ohnishi H

    . Preoperative and postoperative evaluation of cerebral perfusion and vasodilatory capacity with 99mTc-HMPAO SPECT and acetazolamide in childhood moyamoya disease. Stroke 1996;27:282–89 doi:10.1161/01.STR.27.2.282 pmid:8571424

    Abstract/FREE Full Text
14. 14.↵
    2. Kuroda S,
    3. Kashiwazaki D,
    4. Hirata K, et al

    . Effects of surgical revascularization on cerebral oxygen metabolism in patients with moyamoya disease: an 15O-gas positron emission tomographic study. Stroke 2014;45:2717–21 doi:10.1161/STROKEAHA.114.006009 pmid:25116870

    Abstract/FREE Full Text
15. 15.↵
    2. Tanaka Y,
    3. Nariai T,
    4. Nagaoka T, et al

    . Quantitative evaluation of cerebral hemodynamics in patients with moyamoya disease by dynamic susceptibility contrast magnetic resonance imaging: comparison with positron emission tomography. J Cereb Blood Flow Metab 2006;26:291–300 doi:10.1038/sj.jcbfm.9600187 pmid:16049427

    CrossRefPubMed
16. 16.↵
    2. Yun TJ,
    3. Cheon JE,
    4. Na DG, et al

    . Childhood moyamoya disease: quantitative evaluation of perfusion MR imaging—correlation with clinical outcome after revascularization surgery. Radiology 2009;251:216–23 doi:10.1148/radiol.2511080654 pmid:19332853

    CrossRefPubMed
17. 17.↵
    2. Barber PA,
    3. Demchuk AM,
    4. Zhang J, et al

    . Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy: ASPECTS Study Group—Alberta Stroke Programme Early CT Score. Lancet 2000;355:1670–74 doi:10.1016/S0140-6736(00)02237-6 pmid:10905241

    CrossRefPubMedWeb of Science
18. 18.↵
    Research Committee on the Pathology and Treatment of Spontaneous Occlusion of the Circle of Willis; Health Labour Sciences Research Grant for Research on Measures for Intractable Diseases. Guidelines for diagnosis and treatment of moyamoya disease (spontaneous occlusion of the circle of Willis). Neurol Med Chir (Tokyo) 2012;52:245–66 doi:10.2176/nmc.52.245

    CrossRefPubMed
19. 19.↵
    2. Kim SK,
    3. Cho BK,
    4. Phi JH, et al

    . Pediatric moyamoya disease: an analysis of 410 consecutive cases. Ann Neurol 2010;68:92–101 doi:10.1002/ana.21981 pmid:20582955

    CrossRefPubMed
20. 20.↵
    2. Ishii K,
    3. Isono M,
    4. Kobayashi H, et al

    . Temporal profile of angiographical stages of moyamoya disease: when does moyamoya disease progress? Neurol Res 2003;25:405–10 doi:10.1179/016164103101201571 pmid:12870269

    CrossRefPubMed
21. 21.↵
    2. Lee JY,
    3. Kim SK,
    4. Phi JH, et al

    . Posterior cerebral artery insufficiency in pediatric moyamoya disease. J Korean Neurosurg Soc 2015;57:436–39 doi:10.3340/jkns.2015.57.6.436 pmid:26180612

    CrossRefPubMed
22. 22.↵
    2. Acker G,
    3. Fekonja L,
    4. Vajkoczy P

    . Surgical management of moyamoya disease. Stroke 2018;49:476–82 doi:10.1161/STROKEAHA.117.018563 pmid:29343587

    FREE Full Text
23. 23.↵
    2. Bedini G,
    3. Blecharz KG,
    4. Nava S, et al

    . Vasculogenic and angiogenic pathways in moyamoya disease. Curr Med Chem 2016;23:315–45 doi:10.2174/092986732304160204181543 pmid:26861126

    CrossRefPubMed
24. 24.↵
    2. Ishii Y,
    3. Nariai T,
    4. Tanaka Y, et al

    . Practical clinical use of dynamic susceptibility contrast magnetic resonance imaging for the surgical treatment of moyamoya disease. Neurosurgery 2014;74:302–09 doi:10.1227/NEU.0000000000000266 pmid:24335813

    CrossRefPubMed
25. 25.↵
    2. Ladner TR,
    3. Donahue MJ,
    4. Arteaga DF, et al

    . Prior Infarcts, Reactivity, and Angiography in Moyamoya Disease (PIRAMD): a scoring system for moyamoya severity based on multimodal hemodynamic imaging. J Neurosurg 2017;126:495–503 doi:10.3171/2015.11.JNS15562 pmid:26967789

    CrossRefPubMed